NIOX Group (LON:NIOX) Trading Down 0.3% – Here’s Why

NIOX Group Plc (LON:NIOX) shares traded down 0.3% during mid-day trading on Monday . The company traded as low as GBX 62.31 and last traded at GBX 62.80. 947,841 shares changed hands during trading, an increase of 19% from the average session volume of 797,196 shares. The stock had previously closed at GBX 63.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft cut their target price on NIOX Group from GBX 90 to GBX 86 and set a “buy” rating for the company in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of GBX 88.

NIOX Group Stock Performance

The firm has a market capitalization of £262.46 million, a price-to-earnings ratio of 50.24 and a beta of 0.92. The firm’s 50-day moving average price is GBX 65.99 and its two-hundred day moving average price is GBX 69.26. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.94 and a current ratio of 3.73.

About NIOX Group

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.

Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.